Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug combo enters early human testing

NCT ID NCT07027527

Disease control Sponsor: Apogee Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 2 times

Summary

This early-stage trial is testing a combination of two experimental drugs, APG777 and APG990, in 86 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drugs move through the body, comparing them to the existing treatment Dupixent. Participants will receive injections over 24 weeks and be followed for about 82 weeks total.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
APG777 and APG990 (injectable drugs)
What this could lead to
If successful, this could lead to a new treatment option for people with moderate-to-severe eczema that may work differently than current therapies.
What could go wrong
This is an early Phase 1b study focused on safety and drug levels, not yet on effectiveness. The combination may not prove better or safer than existing treatments like Dupixent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

86 people

The number who actually took part.

Started

Jun 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Have a diagnosis of AD that has been present for ≥ 1 year prior to the Screening visit and as determined by the Investigator through participant interview and/or review of the medical history. * Moderate-to-severe AD at Screening and Baseline (Day 1) visits, defined as: a) Eczema Area and Severity Index (EASI) score of ≥ 16, b) vIGA-AD score of ≥ 3, and c) AD affecting ≥10% of body surface area (BSA). * History of inadequate response to treatment with topical medications * Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline (Day 1) visit. Exclusion Criteria * Participation in a prior study with APG777 or APG990. * Prior treatment with protocol-specified monoclonal antibodies (mAbs). * Has used any AD-related topical medications within 7 days prior to Baseline visit. * Has used systemic treatments (other than biologics) and/or phototherapies and/or laser therapy that could affect AD within 4 weeks prior to Baseline visit * History of known hypersensitivity to any of the ingredients in APG777, APG990, or dupilumab. * Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or might interfere with study assessments Note: Additional protocol defined Inclusion/Exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Investigational Site

    Darlinghurst, New South Wales, 2010, Australia

  • Investigational Site

    Kogarah, New South Wales, 2217, Australia

  • Investigational Site

    Westmead, New South Wales, 2145, Australia

  • Investigational Site

    Woolloongabba, Queensland, 4102, Australia

  • Investigational Site

    Carlton, Victoria, 3053, Australia

  • Investigational Site

    East Melbourne, Victoria, 3002, Australia

  • Investigational Site

    Mitcham, Victoria, 3132, Australia

  • Investigational Site

    Parkville, Victoria, 3050, Australia

  • Investigational Site

    Fremantle, Western Australia, 6160, Australia

  • Investigational Site

    London, Ontario, N6H 5L5, Canada

  • Investigational Site

    Peterborough, Ontario, K9J 5K2, Canada

  • Investigational Site

    Richmond Hill, Ontario, L4B 1A5, Canada

  • Investigational Site

    Toronto, Ontario, M4E 1R7, Canada

  • Investigational Site

    Toronto, Ontario, M4W 2N4, Canada

  • Investigational Site

    Toronto, Ontario, M5A 3R6, Canada

  • Investigational Site

    Montreal, Quebec, H1Y 3L1, Canada

  • Investigational Site

    Québec, Quebec, G1W 1S2, Canada

  • Investigational Site

    Sherbrooke, Quebec, J1G 1X9, Canada

  • Investigational Site

    Hamilton, Waitako, 3204, New Zealand

  • Investigational Site

    Auckland, 1051, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.